## Breast Cancer

### Endocrine Therapy

- **Pre-Op Therapy**
  - No Trial Currently Available

- **Surgical Therapy**
  - IRB#9340 - Phase II breast conservation surgery and radiation therapy study

- **Adjuvant Therapy**
  - IRB#15366 - Phase 2 Study of ONT-380 vs. Placebo with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (Applies to Adjuvant, 1st line and beyond HER2+ MBC therapy)

- **1st line MBC Therapy**
  - IRB#15588 SMMART
  - IRB#17504 MonarchE

- **2nd line MBC Therapy**
  - IRB#16379 C31006: An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor Therapy

- **3rd line MBC Therapy**
  - IRB#17461 S1418 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy

- **“Heavily Pre-treated” Therapy**
  - No Trial Currently Available

### ER/PR-POSITIVE HER2 NEGATIVE

- IRB#6256-ISPY2 Investigation of Serial Studies to Predict your Therapeutic response with imaging/molecular

### HER2 POSITIVE

- IRB # 17016 COMPLEMENTET-1: An open-label Phase 3 to evaluate safety and efficacy of ribociclib in combination with letrozole

### “TRIPLE NEGATIVE” EP/PR-NEGATIVE HER2-NEGATIVE

- No Trial Currently Available

---

**Key**

- Open for Enrollment
- In Development
- Enrollment on Hold

---

http://www.ohsu.edu/research/rda/so/knight.php

02/05/2018